Omer Koc, MD
Medical Oncologist
Laryngeal Cancer Lung Cancer Ovarian Cancer Pericardial Mesothelioma Peritoneal Mesothelioma Pleural Mesothelioma Testicular Mesothelioma
Chemotherapy Gene Therapy Pain Management Photodynamic Therapy Targeted Therapy
Dr. Omer Koc did his medical schooling at the Istanbul University Faculty of Medicine and later on did his residency at the Cleveland Clinic Foundation. He has also done a Fellowship at the Case Western Reserve University - University Hospitals. He is a board-certified medical oncologist and currently practices at the Cleveland Clinic Hospital.
Istanbul University Faculty of Medicine
Medical School
Cleveland Clinic Foundation
Residency
Case Western Reserve University - University Hospitals
Fellowship
American Board of Internal Medicine
American Board of Internal Medicine - Oncology
OH State Medical License Active through 2018
CLEVELAND CLINIC HOSPITAL
Languages: English/Spanish
(216) 445-0150
9500 Euclid Ave Taussig Cancer Institute
Read MorePhase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.
Bose P, Perkins EB, Honeycut C, Wellons MD, Stefan T, Jacobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Douglas Figg W, Karp JE, Koc ON, Cooper BW, Luger...; Cancer Chemother. Pharmacol.. 2012-06-01.
See more >>A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
Koç, O. N., Redfern, C., Wiernik, P. H., Rosenfelt, F., Winter, J. N., Carter, W. D., Gold, D. P., Stewart, M. E., Ghalie, R. G., Bender, J. F.; J Immunother. 2010-02-01.
See more >>Time-dependent effect of non-Hodgkin's lymphoma grade on disease-free survival of relapsed/refractory patients treated with high-dose chemotherapy plus autotransplantation
Fu P, van Heeckeren WJ, Wadhwa PD, Bajor DJ, Creger RJ, Xu Z, Cooper BW, Laughlin MJ, Gerson SL, Koç ON, Lazarus HM; Contemp Clin Trials. 2008-03-01.
See more >>